학술논문
Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
Document Type
article
Author
Sooyeon Kho; Kwonjune J. Seung; Helena Huerga; Mathieu Bastard; Palwasha Y. Khan; Carole D. Mitnick; Michael L. Rich; Shirajul Islam; Dali Zhizhilashvili; Lusine Yeghiazaryan; Elena Nikolaevna Nikolenko; Khin Zarli; Sana Adnan; Naseem Salahuddin; Saman Ahmed; Zully Haydee Ruíz Vargas; Amsalu Bekele; Aiman Shaimerdenova; Meseret Tamirat; Alain Gelin; Stalz Charles Vilbrun; Catherine Hewison; Uzma Khan; Molly Franke
Source
Nature Communications, Vol 15, Iss 1, Pp 1-7 (2024)
Subject
Language
English
ISSN
2041-1723
Abstract
Abstract Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT03259269) to estimate the frequency (primary endpoint) among individuals receiving a longer (18-to-20 month) regimen for multidrug- or rifampicin-resistant (MDR/RR) TB who experienced culture conversion. We also conduct Cox proportional hazard regression analyses to identify factors associated with reversion, including comorbidities, previous treatment, cavitary disease at conversion, low body mass index (BMI) at conversion, time to conversion, and number of likely-effective drugs. Of 1,286 patients, 54 (4.2%) experienced reversion, a median of 173 days (97-306) after conversion. Cavitary disease, BMI